Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

393 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Combining gene expression analysis of gastric cancer cell lines and tumor specimens to identify biomarkers for anti-HER therapies-the role of HAS2, SHB and HBEGF.
Ebert K, Haffner I, Zwingenberger G, Keller S, Raimúndez E, Geffers R, Wirtz R, Barbaria E, Hollerieth V, Arnold R, Walch A, Hasenauer J, Maier D, Lordick F, Luber B. Ebert K, et al. Among authors: wirtz r. BMC Cancer. 2022 Mar 9;22(1):254. doi: 10.1186/s12885-022-09335-4. BMC Cancer. 2022. PMID: 35264144 Free PMC article.
Technical validation of an RT-qPCR in vitro diagnostic test system for the determination of breast cancer molecular subtypes by quantification of ERBB2, ESR1, PGR and MKI67 mRNA levels from formalin-fixed paraffin-embedded breast tumor specimens.
Laible M, Schlombs K, Kaiser K, Veltrup E, Herlein S, Lakis S, Stöhr R, Eidt S, Hartmann A, Wirtz RM, Sahin U. Laible M, et al. Among authors: wirtz rm. BMC Cancer. 2016 Jul 7;16:398. doi: 10.1186/s12885-016-2476-x. BMC Cancer. 2016. PMID: 27389414 Free PMC article.
Impact of molecular subtypes on the prediction of distant recurrence in estrogen receptor (ER) positive, human epidermal growth factor receptor 2 (HER2) negative breast cancer upon five years of endocrine therapy.
Laible M, Hartmann K, Gürtler C, Anzeneder T, Wirtz R, Weber S, Keller T, Sahin U, Rees M, Ramaswamy A. Laible M, et al. Among authors: wirtz r. BMC Cancer. 2019 Jul 15;19(1):694. doi: 10.1186/s12885-019-5890-z. BMC Cancer. 2019. PMID: 31307414 Free PMC article.
Androgen receptor expression and response to chemotherapy in breast cancer patients treated in the neoadjuvant TECHNO and PREPARE trial.
Witzel I, Loibl S, Wirtz R, Fasching PA, Denkert C, Weber K, Lück HJ, Huober J, Karn T, Mackelenbergh MV, Marmé F, Schem C, Stickeler E, Untch M, Müller V. Witzel I, et al. Among authors: wirtz r. Br J Cancer. 2019 Dec;121(12):1009-1015. doi: 10.1038/s41416-019-0630-3. Epub 2019 Nov 15. Br J Cancer. 2019. PMID: 31728025 Free PMC article. Clinical Trial.
Cytotoxic T-cell-related gene expression signature predicts improved survival in muscle-invasive urothelial bladder cancer patients after radical cystectomy and adjuvant chemotherapy.
Eckstein M, Strissel P, Strick R, Weyerer V, Wirtz R, Pfannstiel C, Wullweber A, Lange F, Erben P, Stoehr R, Bertz S, Geppert CI, Fuhrich N, Taubert H, Wach S, Breyer J, Otto W, Burger M, Bolenz C, Keck B, Wullich B, Hartmann A, Sikic D; BRIDGE Consortium e.V., Mannheim, Germany. Eckstein M, et al. Among authors: wirtz r. J Immunother Cancer. 2020 May;8(1):e000162. doi: 10.1136/jitc-2019-000162. J Immunother Cancer. 2020. PMID: 32448798 Free PMC article.
CTLA4 promoter hypomethylation is a negative prognostic biomarker at initial diagnosis but predicts response and favorable outcome to anti-PD-1 based immunotherapy in clear cell renal cell carcinoma.
Klümper N, Ralser DJ, Zarbl R, Schlack K, Schrader AJ, Rehlinghaus M, Hoffmann MJ, Niegisch G, Uhlig A, Trojan L, Steinestel J, Steinestel K, Wirtz RM, Sikic D, Eckstein M, Kristiansen G, Toma M, Hölzel M, Ritter M, Strieth S, Ellinger J, Dietrich D. Klümper N, et al. Among authors: wirtz rm. J Immunother Cancer. 2021 Aug;9(8):e002949. doi: 10.1136/jitc-2021-002949. J Immunother Cancer. 2021. PMID: 34446578 Free PMC article.
393 results